title: Cellular elimination of 2',2'-difluorodeoxycytidine 5'-triphosphate: a mechanism of self-potentiation.
abstract: 2',2'-Difluorodeoxycytidine (dFdC, Gemcitabine) is a deoxycytidine analogue which, after phosphorylation to the 5'-di- and 5'-triphosphate (dFdCTP), induces inhibition of DNA synthesis and cell death. We examined the values for elimination kinetics of cellular dFdCTP and found they were dependent on cellular concentration after incubation of CCRF-CEM cells with dFdC and washing into drug-free medium. When the drug was washed out at low cellular dFdCTP levels (less than 50 microM), dFdCTP elimination was linear (t1/2 = 3.3 h), but it became biphasic at intracellular dFdCTP levels greater than 100 microM. Although the initial elimination rate was similar at all concentrations, at higher concentrations the terminal elimination rate increased with increasing cellular dFdCTP concentration, with a nearly complete inhibition of dFdCTP elimination at 300 microM. The deamination product 2',2'-difluorodeoxyuridine was the predominant extracellular catabolite at low cellular dFdCTP concentrations, whereas at high dFdCTP concentrations dFdC was the major excretion product. The dCMP deaminase inhibitor 3,4,5,6-tetrahydrodeoxyuridine transformed the monophasic dFdCTP degradation seen at low dFdCTP levels into a biphasic process, whereas the deoxycytidine deaminase inhibitor 3,4,5,6-tetrahydrouridine had no effect on dFdCTP elimination. An in situ assay indicated that dCMP deaminase activity was inhibited in whole cells, an action that was associated with a decreased dCTP:dTTP value. In addition, dFdCTP inhibited partially purified dCMP deaminase with a 50% inhibitory concentration of 0.46 mM. We conclude that dFdC-induced inhibition of dCMP deaminase resulted in a decrease of dFdCTP catabolism, contributing to the concentration-dependent elimination kinetics. This action constitutes a self-potentiation of dFdC activity.
authors.affiliation: Department of Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston 77030.
authors.forename: V
authors.initials: V
authors.lastname: Heinemann
authors.forename: Y Z
authors.initials: YZ
authors.lastname: Xu
authors.forename: S
authors.initials: S
authors.lastname: Chubb
authors.forename: A
authors.initials: A
authors.lastname: Sen
authors.forename: L W
authors.initials: LW
authors.lastname: Hertel
authors.forename: G B
authors.initials: GB
authors.lastname: Grindey
authors.forename: W
authors.initials: W
authors.lastname: Plunkett
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000378:metabolism* / Q000494:pharmacology; D002460:Cell Line; D003570:Cytidine Triphosphate / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000378:metabolism / Q000494:pharmacology; D003844:DCMP Deaminase / Q000037:antagonists & inhibitors; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000494:pharmacology; D003854:Deoxyribonucleotides / Q000494:pharmacology; D006801:Humans; D007700:Kinetics; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma; D012265:Ribonucleotides / Q000302:isolation & purification / Q000378:metabolism; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D003854:Deoxyribonucleotides; D012265:Ribonucleotides; D003841:Deoxycytidine; C054403:2',2'-difluorodeoxycytidine 5'-triphosphate; D003570:Cytidine Triphosphate; D003844:DCMP Deaminase; D000093542:Gemcitabine